Mereo BioPharma has successfully completed the merger with OncoMed, and now the focus shifts firmly back to the pipeline. Initial data from the Phase II study in osteogenesis imperfecta (OI) with its leading rare disease asset, BPS-804, are due in the coming weeks, and top-line data for the full trial in Q419. The Phase II study with MPH-966 in alpha-1 anti-trypsin deficiency (AATD) is due to report top-line data around the year-end. At the same time, Mereo has strengthened the out-licensing packages of non-rare disease assets; notably the outline for a Phase III programme with BCT-197 has been agreed with the FDA, thereby raising the likelihood of BCT197 being partnered by year-end. We value Mereo at 506p/share or $25.59/ADS.
08 May 2019
Focus shifts back to imminent data
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Focus shifts back to imminent data
- Published:
08 May 2019 -
Author:
Mick Cooper PhD -
Pages:
4
Mereo BioPharma has successfully completed the merger with OncoMed, and now the focus shifts firmly back to the pipeline. Initial data from the Phase II study in osteogenesis imperfecta (OI) with its leading rare disease asset, BPS-804, are due in the coming weeks, and top-line data for the full trial in Q419. The Phase II study with MPH-966 in alpha-1 anti-trypsin deficiency (AATD) is due to report top-line data around the year-end. At the same time, Mereo has strengthened the out-licensing packages of non-rare disease assets; notably the outline for a Phase III programme with BCT-197 has been agreed with the FDA, thereby raising the likelihood of BCT197 being partnered by year-end. We value Mereo at 506p/share or $25.59/ADS.